Psychedelics, mystical experience, and therapeutic efficacy: A systematic review

K Ko, G Knight, JJ Rucker, AJ Cleare - Frontiers in psychiatry, 2022 - frontiersin.org
The mystical experience is a potential psychological mechanism to influence outcome in
psychedelic therapy. It includes features such as oceanic boundlessness, ego dissolution …

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science

AK Schlag, J Aday, I Salam… - Journal of …, 2022 - journals.sagepub.com
Background: Despite an increasing body of research highlighting their efficacy to treat a
broad range of medical conditions, psychedelic drugs remain a controversial issue among …

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis

K Ko, EI Kopra, AJ Cleare, JJ Rucker - Journal of Affective Disorders, 2023 - Elsevier
Background Psychedelic therapy shows promise for Major Depressive Disorder, especially
when treatment-resistant, as well as life-threatening illness distress. The objective of this …

[图书][B] Philosophy of psychedelics

C Letheby - 2021 - books.google.com
Recent clinical trials show that psychedelics such as LSD and psilocybin can be given safely
in controlled conditions, and can cause lasting psychological benefits with one or two …

Case analysis of long-term negative psychological responses to psychedelics

R Bremler, N Katati, P Shergill, D Erritzoe… - Scientific Reports, 2023 - nature.com
Recent controversies have arisen regarding claims of uncritical positive regard and hype
surrounding psychedelic drugs and their therapeutic potential. Criticisms have included that …

Designer drugs: mechanism of action and adverse effects

D Luethi, ME Liechti - Archives of toxicology, 2020 - Springer
Psychoactive substances with chemical structures or pharmacological profiles that are
similar to traditional drugs of abuse continue to emerge on the recreational drug market …

Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants

NL Galvão-Coelho, W Marx, M Gonzalez, J Sinclair… - …, 2021 - Springer
Rationale Major depressive disorder is one of the leading global causes of disability, for
which the classic serotonergic psychedelics have recently reemerged as a potential …

Molecular mechanisms of psilocybin and implications for the treatment of depression

S Ling, F Ceban, LMW Lui, Y Lee, KM Teopiz… - CNS drugs, 2022 - Springer
Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify
and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are …

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

JM Rootman, P Kryskow, K Harvey, P Stamets… - Scientific reports, 2021 - nature.com
The use of psychedelic substances at sub-sensorium 'microdoses', has gained popular
academic interest for reported positive effects on wellness and cognition. The present study …

Ketamine and serotonergic psychedelics: an update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment

JN Johnston, B Kadriu, J Allen, JR Gilbert, ID Henter… - …, 2023 - Elsevier
The discovery of ketamine as a rapid-acting antidepressant spurred significant research to
understand its underlying mechanisms of action and to identify other novel compounds that …